Company
Every investor coverage indicates participated in a round US Securities and Exchange Commission raised.
Companies US Securities and Exchange Commission acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
Stories naming US Securities and Exchange Commission. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
A fintech roundup: Bench's closure and sale to Employer.com, multiple acquisitions, fresh raises at Float Financial, Open Ledger, NomuPay and Buk, Robinhood's regulator settlement, and Groww's listing plans.
ASX-listed drug developer ChemGenex will quit NASDAQ and SEC reporting to cut compliance costs, and three directors step down in July while staying on as advisers.
Australian drug developer Pharmaxis has won NASDAQ approval to trade its ADRs under ticker PXSLY, issuing no new shares; SEC registration is expected around 26 August 2005 before trading begins.
Also GBS Ventures·GBS Ventures